FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2581401244> ?p ?o ?g. }

• W2581401244 abstract "Abstract Abstract 2027 Poster Board II-4 Background. The prognosis of Ph+ adult ALL patients treated with standard therapies, including multi-agent chemotherapy, Imatinib, and allogeneic stem cell transplantation, is still dismal, due to a high risk of relapse. Dasatinib and Nilotinb are second generation TKIs developed to overcome the problem of resistance to Imatinib in relapsed Ph+ leukemias. Design and Methods. We retrospectively evaluated the single center experience on therapy efficacy of Dasatinib, Nilotinib, and experimental third generation TKIs, administered as second or subsequent line of therapy on 25 relapsed Ph+ adult ALL patients. All patients were previously treated with Imatinib. The median age at time of diagnosis was 50 years (range 18-74), 17 patients were male and 8 female. Ten patients presented a BCR-ABL P190 fusion protein and corresponding fusion transcript, the remaining a BCR-ABL P210. Nineteen patients received Dasatinib, 2 patients Nilotinib and the remaining 4 patients were treated with third generation TKIs. Fourteen patients (56%) were in first relapse, and 7 (28%), 3 (12%) and 1 (4%) were in second, third and fourth relapse, respectively. A mutational analysis was performed in all the patients before TKIs (9 wild type, 16 mutated, including T315I) and at the time of subsequent relapse; gene expression profiling, SNPArray (6.0 Affymetrix chip), and Ikaros deletions were also analyzed. Results. 13 out of 25 patients (52%) obtained a haematological response (HR) (11 patients treated with Dasatinib, 1 patient with Nilotinib and 1 patient with a third generation experimental TKI). 10 patients obtained also a cytogenetic response (CyR) and 6 patients a molecular response (MolR). With a median follow up of 10.8 months (range 2-29 months), median duration of HR, CyR and MolR were 117 days (range 14-385 days); progression free survival were 162 days with Dasatinib and 91 days with Nilotinib. Overall survival was 25.8 months. Interestingly, in 6 out of 9 wild-type patients, treated with Dasatinib, the mutational analysis showed the emergence of T315I or F317I mutation at the time of relapse. Conclusion. Second and third generation TKIs represent a valid approach in relapsed Ph+ adult ALL patients; the subsequent relapse is often associated to the emergence of mutation, conferring resistance to TKIs. Since TKIs are different and have different efficacy, pharmacokinetic, pharmacodynamic and toxicity profiles, and since are all effective, an alternative experimental option for the treatment of Ph+ ALL could be a combination or a rotation of two or more than two TKIs. Moreover, the addition of new promising targeted molecules, such as Aurora kinase or T315I inhibitors may contribute to overcome the problem of resistance to TKIs. Acknowledgments. Work supported by European LeukemiaNet, FIRB 2006, AIRC, AIL, COFIN, University of Bologna and BolognAIL. Disclosures: No relevant conflicts of interest to declare." @default.
• W2581401244 created "2017-02-03" @default.
• W2581401244 creator A5000893813 @default.
• W2581401244 creator A5007773747 @default.
• W2581401244 creator A5009003698 @default.
• W2581401244 creator A5016041461 @default.
• W2581401244 creator A5023456714 @default.
• W2581401244 creator A5023529754 @default.
• W2581401244 creator A5029144895 @default.
• W2581401244 creator A5031714115 @default.
• W2581401244 creator A5037270007 @default.
• W2581401244 creator A5037413392 @default.
• W2581401244 creator A5042328462 @default.
• W2581401244 creator A5044224344 @default.
• W2581401244 creator A5044624520 @default.
• W2581401244 creator A5049545269 @default.
• W2581401244 creator A5060457186 @default.
• W2581401244 creator A5063427645 @default.
• W2581401244 creator A5064268164 @default.
• W2581401244 creator A5067954471 @default.
• W2581401244 creator A5068277587 @default.
• W2581401244 creator A5069471644 @default.
• W2581401244 creator A5072253025 @default.
• W2581401244 creator A5073761054 @default.
• W2581401244 creator A5074502321 @default.
• W2581401244 creator A5086068112 @default.
• W2581401244 date "2009-11-20" @default.
• W2581401244 modified "2023-10-01" @default.
• W2581401244 title "Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience." @default.
• W2581401244 doi "https://doi.org/10.1182/blood.v114.22.2027.2027" @default.
• W2581401244 hasPublicationYear "2009" @default.
• W2581401244 type Work @default.
• W2581401244 sameAs 2581401244 @default.
• W2581401244 citedByCount "0" @default.
• W2581401244 crossrefType "journal-article" @default.
• W2581401244 hasAuthorship W2581401244A5000893813 @default.
• W2581401244 hasAuthorship W2581401244A5007773747 @default.
• W2581401244 hasAuthorship W2581401244A5009003698 @default.
• W2581401244 hasAuthorship W2581401244A5016041461 @default.
• W2581401244 hasAuthorship W2581401244A5023456714 @default.
• W2581401244 hasAuthorship W2581401244A5023529754 @default.
• W2581401244 hasAuthorship W2581401244A5029144895 @default.
• W2581401244 hasAuthorship W2581401244A5031714115 @default.
• W2581401244 hasAuthorship W2581401244A5037270007 @default.
• W2581401244 hasAuthorship W2581401244A5037413392 @default.
• W2581401244 hasAuthorship W2581401244A5042328462 @default.
• W2581401244 hasAuthorship W2581401244A5044224344 @default.
• W2581401244 hasAuthorship W2581401244A5044624520 @default.
• W2581401244 hasAuthorship W2581401244A5049545269 @default.
• W2581401244 hasAuthorship W2581401244A5060457186 @default.
• W2581401244 hasAuthorship W2581401244A5063427645 @default.
• W2581401244 hasAuthorship W2581401244A5064268164 @default.
• W2581401244 hasAuthorship W2581401244A5067954471 @default.
• W2581401244 hasAuthorship W2581401244A5068277587 @default.
• W2581401244 hasAuthorship W2581401244A5069471644 @default.
• W2581401244 hasAuthorship W2581401244A5072253025 @default.
• W2581401244 hasAuthorship W2581401244A5073761054 @default.
• W2581401244 hasAuthorship W2581401244A5074502321 @default.
• W2581401244 hasAuthorship W2581401244A5086068112 @default.
• W2581401244 hasConcept C121608353 @default.
• W2581401244 hasConcept C126322002 @default.
• W2581401244 hasConcept C143998085 @default.
• W2581401244 hasConcept C2777413986 @default.
• W2581401244 hasConcept C2777583451 @default.
• W2581401244 hasConcept C2778729363 @default.
• W2581401244 hasConcept C2778820342 @default.
• W2581401244 hasConcept C2779536868 @default.
• W2581401244 hasConcept C2911091166 @default.
• W2581401244 hasConcept C3019892230 @default.
• W2581401244 hasConcept C71924100 @default.
• W2581401244 hasConceptScore W2581401244C121608353 @default.
• W2581401244 hasConceptScore W2581401244C126322002 @default.
• W2581401244 hasConceptScore W2581401244C143998085 @default.
• W2581401244 hasConceptScore W2581401244C2777413986 @default.
• W2581401244 hasConceptScore W2581401244C2777583451 @default.
• W2581401244 hasConceptScore W2581401244C2778729363 @default.
• W2581401244 hasConceptScore W2581401244C2778820342 @default.
• W2581401244 hasConceptScore W2581401244C2779536868 @default.
• W2581401244 hasConceptScore W2581401244C2911091166 @default.
• W2581401244 hasConceptScore W2581401244C3019892230 @default.
• W2581401244 hasConceptScore W2581401244C71924100 @default.
• W2581401244 hasLocation W25814012441 @default.
• W2581401244 hasOpenAccess W2581401244 @default.
• W2581401244 hasPrimaryLocation W25814012441 @default.
• W2581401244 hasRelatedWork W1510901763 @default.
• W2581401244 hasRelatedWork W1965303921 @default.
• W2581401244 hasRelatedWork W2057796192 @default.
• W2581401244 hasRelatedWork W2058216377 @default.
• W2581401244 hasRelatedWork W2085342571 @default.
• W2581401244 hasRelatedWork W2153801741 @default.
• W2581401244 hasRelatedWork W2270987378 @default.
• W2581401244 hasRelatedWork W2324712256 @default.
• W2581401244 hasRelatedWork W2344488712 @default.
• W2581401244 hasRelatedWork W2530803155 @default.
• W2581401244 hasRelatedWork W2563844599 @default.
• W2581401244 hasRelatedWork W2566062550 @default.
• W2581401244 hasRelatedWork W2586648068 @default.
• W2581401244 hasRelatedWork W2596629713 @default.
• W2581401244 hasRelatedWork W2626925928 @default.
• W2581401244 hasRelatedWork W2953638685 @default.

• next